Desmopressin Acetate Tablets Recalled by Manufacturer for Subpotency
RemedyRepack Inc. is recalling Desmopressin Acetate Tablets due to subpotency. The affected tablets may not provide the intended therapeutic effect.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall with identified manufacturing defect affecting drug potency. No illnesses or injuries have been reported, but subpotency in a prescription medication poses risk of therapeutic failure and potential patient harm from ineffective treatment.
Plain-English summary
RemedyRepack Inc. is recalling Desmopressin Acetate Tablet, 0.2 mg, in 100-count boxes due to subpotency. The affected product includes NDC 70518-3493-00 with lot numbers B1817019-082222 (expiration 02/24/2023) and B1819127-082322 (expiration 02/26/2023).
The repackaged tablets were found to be subpotent, meaning they may not contain the full intended amount of active pharmaceutical ingredient and may not provide the expected therapeutic effect.
The product was distributed to two customers in Michigan. Patients who received this medication should contact their healthcare provider to discuss their current medication and treatment options. Do not discontinue use without consulting your healthcare provider.
The recalled product
- Product
- Desmopressin Acetate Tablet, 0.2 mg, 100-count box, Rx only, Source NDC: 23155-0490-01; MFG: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816; Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC #: 70518-3493-00.
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Tablet
- Hazard
- Affected units
- 9
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # B1817019-082222
- Exp. 02/24/2023
- B1819127-082322
- Exp. 02/26/2023
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · sub potency
See all →- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- LowSinuFrin Nasal Decongestant Recalled for Sub-Potency Nationwide
FDA (Drugs) · 2024-07-03
- SeverePrescription Drug Javygtor Recalled for Sub-Potency and Powder Discoloration
FDA (Drugs) · 2024-05-15